

# MDL 19301

Catalog No: tcsc0018438



## Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

89388-38-5

**Formula:**

$C_{15}H_{21}NS_2$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**


279.46

## Product Description

MDL 19301 is a nonsteroidal, anti-inflammatory agent.

***In Vivo:*** Oral administration of MDL 19301 inhibits rat paw edema induced by carrageenan ( $ED_{30}=4.8$  mg/kg) or an Arthus reaction

(ED<sub>30</sub>=8.2 mg/kg p.o.). The oral dose which induces gastric ulceration in 50% of fasted rats is greater than 1,000 mg/kg, demonstrating a more favorable therapeutic ratio than conventional nonsteroidal anti-inflammatory agents. The anti-inflammatory activity of MDL 19301, but not that of MDL 16,861, is attenuated by co-administration of an inhibitor of drug metabolite (SKF525A). This suggests that MDL 19301 is a prodrug of MDL 16,861 and this phenomenon would explain its lack of ulcerogenicity. Additional anti-inflammatory properties of MDL 19301 include inhibition of carrageenan pleurisy, adjuvant arthritis, and HOAc-induced writhing. Other pharmacological data indicate that MDL 19301 administration results in inhibition of prostaglandin synthesis; inhibition of arachidonic acid-induced, but not prostaglandin-E<sub>2</sub>-induced, diarrhea in mice; and inhibition of ex vivo arachidonic-acid-induced, but not ADP-induced, rat platelet aggregation. MDL 19301 and MDL 16,861 are unexpectedly weak antipyretic agents in rats<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!